| Literature DB >> 22206445 |
Geir Hallan1, Birgitte Espehaug, Ove Furnes, Helge Wangen, Paul J Høl, Peter Ellison, Leif I Havelin.
Abstract
BACKGROUND ANDEntities:
Mesh:
Substances:
Year: 2011 PMID: 22206445 PMCID: PMC3278649 DOI: 10.3109/17453674.2011.645194
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Figure 1.The Titan cemented femoral stem.
Patient characteristics and femoral stem epidemiology
| 1987–1995 | 1996–2000 | 2001–2008 | |
|---|---|---|---|
| No. of hips | 2,895 | 2,635 | 4,483 |
| No. of hospitals with > 100 hips in the period | 8 | 8 | 8 |
| Patient age (median, range) | 73.8 | 74.7 | 74.7 |
| Sex (% males) | 28 | 26 | 27 |
| Diagnosis (% osteoarthritis) | 70 | 74 | 78 |
| Stem size (%) | |||
| T ≤ 11 | 29 | 32 | 39 |
| T = 12–13 | 45 | 48 | 44 |
| T ≥ 14 | 26 | 20 | 17 |
| Stem offset (% lateralized stems) | 4.5 | 5.1 | 9.4 |
| Femoral head size (%) | |||
| 28 mm | 26 | 95 | 100 |
| 32 mm | 74 | 5 | 0 |
| Femoral head material (%) | |||
| Steel | 80 | 52 | 0 |
| Cobalt chrome | 0 | 44 | 95 |
| Others | 20 | 7 | 4 |
| Bone cement (%) | |||
| Palacos | 16 | 4 | 0 |
| Palacos with Gentamycin | 79 | 95 | 61 |
| Refobacin Palacos | 0 | 0 | 5 |
| Palacos R+G | 0 | 0 | 17 |
| Refobacin Bone Cement R | 0 | 0 | 14 |
| Simplex | 4 | 0 | 0 |
| Others/Missing | 1 | 1 | 3 |
Simplex-Erythromycine/Colistin, Palacos E-Flow, Simplex with Tobramycine, Cemex with Gentamycin, SmartSet HV, Cemex Systeme Genta Fast, Optipac Refobacine Bonecement.
Kaplan-Meier survival and Cox regression analysis with adjustments made for age, sex, and diagnosis. The endpoint was revision of the stem for aseptic loosening
| Relative risk of revision (95% CI) | p-value | Survival at 7 years (95% CI) | |
|---|---|---|---|
| 1987–1995 | 1.3 (0.8–2.1) | 0.1 | 99.0 (98.6–99.4) |
| 1996–2000 (ref.) | 1 | – | 99.0 (98.6–99.5) |
| 2001–2008 | 4.7 (3.0–7.4) | < 0.001 | 95.7 (94.6–96.8) |
Figure 2.Survival of the stem in stratified time periods. The endpoint was revision of the stem for aseptic loosening.
Figure 3.Example of a revision case 3 years after surgery (A), and 5 years after surgery showing extensive osteolysis (B and C). Another case at 2 years (D) and 6 years (E) with a similar appearance.
Cox regression analysis with adjustments for time period and diagnosis. The impact of age, sex, neck option, femoral stem size, and femoral head size. The endpoint was stem revision for aseptic loosening
| Relative risk of revision (95% CI) | p-value | |
|---|---|---|
| Age | 0.9 (0.9–1.0) | < 0.001 |
| Sex | 2.5 (1.9–3.4) | < 0.001 |
| Neck option: standard (ref.) | 1 | – |
| lateralized | 3.3 (2.3–4.8) | < 0.00 1 |
| Stem size: | ||
| ≤ 11 | 2.2 (1.4–3.5) | < 0.001 |
| 12–13 | 1.1 (0.7–1.8) | 0.7 |
| ≥ 14 (ref.) | 1 | – |
| Femoral head size: | ||
| 32 mm (ref.) | 1 | – |
| 28 mm | 0.9 (0.5–1.6) | 0.8 |
Female sex was the reference group (RR = 1).
Figure 4.Survival of the stem according to femoral offset (standard vs. lateralized). The endpoint was stem revision for any reason.
The total offset (stem type and head/neck length) stratified into 5 groups. Relative risk (RR) of stem revision for aseptic stem loosening (Cox, adjusted for sex, age, stem size, and femoral head size)
| Total offset | No. of hips | No. of standard stems | No. of lateralized stems | RR (95% CI) |
|---|---|---|---|---|
| ≤ 3 mm | 2,969 | 2,969 | 0 | – |
| 3–5 mm | 4,391 | 4,391 | 0 | 1.6 (1.1–2.5) |
| 5–7 mm | 1,411 | 1,411 | 0 | 1.4 (0.8–2.4) |
| 7–9 mm | 495 | 238 | 257 | 5.1 (3.0–8.9) |
| > 9 mm | 504 | 86 | 418 | 3.9 (2.2–6.9) |
Figure 5.Survival of the stem according to stem size. The endpoint was stem revision for any reason.